These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37945404)

  • 21. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
    Houédé N; Locker G; Lucas C; Parra HS; Basso U; Spaeth D; Tambaro R; Basterretxea L; Morelli F; Theodore C; Lusuardi L; Lainez N; Guillot A; Tonini G; Bielle J; Del Muro XG
    BMC Cancer; 2016 Sep; 16(1):752. PubMed ID: 27664126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
    Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
    Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
    Wong RL; Ferris LA; Do OA; Holt SK; Ramos JD; Crabb SJ; Sternberg CN; Bellmunt J; Ladoire S; De Giorgi U; Harshman LC; Vaishampayan UN; Necchi A; Srinivas S; Pal SK; Niegisch G; Dorff TB; Galsky MD; Yu EY
    Oncologist; 2021 Dec; 26(12):1026-1034. PubMed ID: 34355457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
    Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
    Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
    Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
    JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
    Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
    J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
    [No Abstract]   [Full Text] [Related]  

  • 30. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
    ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
    Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
    Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
    Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
    Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Iida K; Inoue K; Tachibana A; Yoshikawa T; Sakamoto K; Ohnishi M; Maesaka F; Takamatsu N; Mieda K; Ohmori C; Matsubara T; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Int J Clin Oncol; 2024 Sep; 29(9):1311-1325. PubMed ID: 38888683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma.
    Doshi GK; Li H; Burcu M; Annavarapu S; Wells K; Imai K; Moreno BH; Singhal P; Mamtani R
    Front Oncol; 2023; 13():1210208. PubMed ID: 37849801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
    BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
    Bilé-Silva A; Lopez-Beltran A; Blanca A; Lopez-Rios F; Gómez-Gómez E; Cimadamore A; Montironi R; Vau N; Cheng L
    Expert Opin Biol Ther; 2023 May; 23(5):407-418. PubMed ID: 37036223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
    Jones RJ; Crabb SJ; Linch M; Birtle AJ; McGrane J; Enting D; Stevenson R; Liu K; Kularatne B; Hussain SA
    Br J Cancer; 2024 Apr; 130(6):897-907. PubMed ID: 38191608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.